Summary:
A randomized double blind placebo and active controlled parallel group phase 2 study to evaluate PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy.
Qualified Participants Must:
• Be between 18 and 80 years of age
•
Have a diagnosis of Type 2 diabetes mellitus
•
Have a presence of ongoing pain due to DPN for at least 6 months
•
Other inclusion/exclusion criteria apply
Qualified Participants May Receive:
Compensation for your time and travel per each completed visit.